Daiichi Sankyo plans $133 mn investment to strengthen biopharma facilities

Daiichi Sankyo Company Limited will making an investment of Yen 15 billion (about $ 133 million) to optimise and enhance its manufacturing capabilities to support its growing antibody drug conjugate (ADC) pipeline. 

“This strategic investment will bolster our leadership and expertise in ADC manufacturing, as we apply our proprietary ADC technology to more than two dozen biologics in preclinical or early stage development. Our manufacturing capacities will more than triple by 2021, affording us greater flexibility for research and development, and strengthening our anticipated future commercial production,” said Katsumi Fujimoto, senior executive officer, head of supply chain division, Daiichi Sankyo.

Daiichi Sankyo